Advertisement

Neurological Sciences

, Volume 39, Issue 12, pp 2021–2031 | Cite as

Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis

  • Qiuxiang Xiao
  • Shaochun Yang
  • Guanfu Ding
  • Muyun LuoEmail author
Review Article

Abstract

Glioblastoma is one of the most common primary brain tumors in adults. The current treatment strategies failed to achieve satisfactory outcomes. Anti-vascular endothelial growth factor (anti-VEGF) agents have been proposed to enhance the survival and quality of life in these patients. To investigate this, different databases were searched in addition to hand searching. Relevant studies were screened and only ten randomized controlled trials (RCTs) met the eligibility criteria; six of them were considered for meta-analysis. Eligible RCTs were assessed regarding risk of bias using the Cochrane tool. Relevant data were extracted and meta-analysis was conducted using the random effects model analysis on RevMan software. One thousand seventy-eight patients in the anti-VEGF group and 946 patients in the control group were available for analysis. No statistically significant improvement in the overall survival (OS) was detected for anti-VEGF (OR 0.87, 95% CI 0.7–1.09, p = 0.23) or bevacizumab subgroup (OR 0.84, 95% CI 0.65–1.08, p = 0.17) compared to standard therapy alone. However, the progression-free survival (PFS) showed a significant improvement with both anti-VEGF (OR 0.76, 95% CI 0.65–0.89, p = 0.0007) and bevacizumab subgroup (OR 0.75, 95% CI 0.65–0.87, p = 0.0001). In conclusion, anti-VEGF agents can improve the PFS but not OS in glioblastoma patients. The current evidence is not satisfactory to declare a new therapeutic line. Further RCTs with sharply determined outcomes and assessment methods are required.

Keywords

Anti-VEGF Bevacizumab Glioblastoma Survival Meta-analysis 

Abbreviations

OS

overall survival

PFS

progression-free survival

VEGF

vascular endothelial growth factor

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology 17 Suppl 4:iv1–iv62CrossRefPubMedGoogle Scholar
  2. 2.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMedGoogle Scholar
  4. 4.
    Das S, Marsden PA (2013) Angiogenesis in glioblastoma. N Engl J Med 369:1561–1563CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027CrossRefPubMedGoogle Scholar
  6. 6.
    Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591CrossRefPubMedGoogle Scholar
  7. 7.
    Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Rev Clin Oncol 6:24–40CrossRefGoogle Scholar
  8. 8.
    Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology 17:708–717CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, Boerman D, de Vos FYF, Dinjens WNM, Enting RH, Taphoorn MJB, van den Berkmortel FWPJ, Jansen RLH, Brandsma D, Bromberg JEC, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–953CrossRefPubMedGoogle Scholar
  10. 10.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMedGoogle Scholar
  12. 12.
    Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O et al (2016) Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neuro-Oncol 127:569–579CrossRefGoogle Scholar
  13. 13.
    Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, DeGroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS (2017) Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O 6-methylguanine–DNA met. J Clin Oncol 35:343–351CrossRefPubMedGoogle Scholar
  15. 15.
    Duerinck J, Du Four S, Vandervorst F, D’Haene N, Le Mercier M, Michotte A et al (2016) Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. J Neuro-Oncol 128:147–155CrossRefGoogle Scholar
  16. 16.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740CrossRefPubMedGoogle Scholar
  17. 17.
    Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CSB, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G, CABARET/COGNO investigators, Rosenthal MA (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-Oncology 17:1504–1513CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Giovagnoli AR (1993) Crossed aphasia. Report of a rare case in a glioblastoma patient. Neurol Sci 14:329–332CrossRefGoogle Scholar
  19. 19.
    Schoenhuber R, Vescovin E, Calcaterra Merli GA (1983) Temporal lobe glioblastoma presenting as Raeder paratrigeminal syndrome. Neurol Sci 4:117–119CrossRefGoogle Scholar
  20. 20.
    Mahta A, Buhl R, Huang H, Jansen O, Kesari S, Ulmer S (2013) Sellar and supra-sellar glioblastoma masquerading as a pituitary macroadenoma. Neurol Sci 34:605–607CrossRefPubMedGoogle Scholar
  21. 21.
    Salmaggi A, Duri S, Silvani A, Gaviani P, Milanesi I, Casali C, Di Meco F. Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. Neurol Sci 2011; 32: 241–245Google Scholar
  22. 22.
    Liang H, Ding X, Zhou C, Zhang Y, Xu M, Zhang C, Xu L (2012) Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol Sci 33:1057–1062CrossRefPubMedGoogle Scholar
  23. 23.
    Silvani A, Eoli M, Salmaggi A, Erbetta A, Fariselli L, Boiardi A (2002) Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. Neurol Sci 23:219–224CrossRefPubMedGoogle Scholar
  24. 24.
    Boiardi A, Eoli M, Pozzi A, Salmaggi A, Broggi G, Silvani A (1999) Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Neurol Sci 20:43–48CrossRefGoogle Scholar
  25. 25.
    Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N (2014) Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev (9).  https://doi.org/10.1002/14651858.CD008218.pub3
  26. 26.
    Yang S-B, Gao K-D, Jiang T, Cheng S-J, Li W-B (2017) Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials. Oncotarget 8:57337–57344PubMedPubMedCentralGoogle Scholar
  27. 27.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMedGoogle Scholar
  28. 28.
    Abushouk AI, Ismail A, Salem AMA, Afifi AM, Abdel-Daim MM (2017) Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomed Pharmacother 90:935–946CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyThe first Affiliated Hospital of Gannan Medical UniversityGanzhouChina
  2. 2.Department of NeurosurgeryThe first Affiliated Hospital of Gannan Medical UniversityGanzhouChina

Personalised recommendations